PODD

INSULET CORP

Healthcare • USA

Apr 05 • 04:00PM ET
324.75
+2.73 (+0.85%)
Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes mana ... read more

Full Time Employees 3,000
Phone 978 600 7000
Website https://www.insulet.com
CEO Dr. James R. Hollingshead Ph.D.
IPO Date 2007-05-15
Sector Healthcare
Industry Medical - Devices
Address 100 Nagog Park, Acton, MA 01720
Balance Sheet
Total Cash $1,283,100,000
Total Debt $1,695,400,000
Current Ratio 4.47
Quick Ratio 3.24
Profitability
Gross Margin 70.39%
Net Margin 18.29%
ROE 30.22%
ROA 11.43%
ROIC 15.44%
Balance Sheet
Total Cash $1,283,100,000
Total Debt $1,695,400,000
Current Ratio 4.47
Quick Ratio 3.24
Profitability
Gross Margin 70.39%
Net Margin 18.29%
ROE 30.22%
ROA 11.43%
ROIC 15.44%
Name INSULET CORP Sector Healthcare Currency USD Relative Volume 1.79 Market Cap 17223
Current Ratio 3.58 Dividend / Share 0.0 EPS 5.78 Revenue 2071600000 P/S 8.3
P/E 41.2 Beta 0.87 Income 418300000 Volume 1337043 Average Volume 745569
Distance to 200DMA 1.86% 200 DMA 240.79 50 DMA 269.86 ROA 14.4 ROE 40.6
Distance to 50DMA -9.12% Return 1Y 48.77% Return YTD -6.06% Forward PE Qtly Growth YOY
Debt/Eq 1.55 P/B 14.2 Dividend Yield 0.0% Net Margin 20.19% Payout Ratio 0.0
Performance
52 Week Range 0.0%
Distance to 200DMA 0.0%
Day Change Percent $0.00

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $902,600,000
Total Debt $1,398,300,000
Current Ratio 3.68%
Quick Ratio 2.53%
Profitability
Gross Margin 70.39%
Net Margin 18.29%
ROE 30.22%
ROA 11.43%
ROIC 15.44%
Valuation
Price to Earnings 56.74
Price to Book 17.15
Price to Sales 10.38
Price to Free Cash Flow 81.27
Dividends
Payout Ratio 0.00%
Dividend Yield 0.00%
Dividend Amount $0.00
Performance
52 Week Range 0.0%
Distance to 200DMA 0.0%
Day Change Percent $0.00
Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes mana ... read more

Full Time Employees 3,000
Phone 978 600 7000
Website https://www.insulet.com
CEO Dr. James R. Hollingshead Ph.D.
IPO Date 2007-05-15
Sector Healthcare
Address 100 Nagog Park, Acton, MA 01720
Histogram - Daily

Balance Sheet
Total Cash $902,600,000
Total Debt $1,398,300,000
Current Ratio 3.68%
Quick Ratio 2.53%
Profitability
Gross Margin 0.6940%
Net Margin 0.2120%
ROE 0.46%
ROA 0.15%
Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes mana ... read more

Full Time Employees 3,000
Phone 978 600 7000
Website https://www.insulet.com
CEO Dr. James R. Hollingshead Ph.D.
IPO Date 2007-05-15
Sector Healthcare
Address 100 Nagog Park, Acton, MA 01720
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

2025-05-15 10:50:20 - zacks.com
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

Insulet Corporation's NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500.

2025-05-14 08:46:41 - marketbeat.com
Outlier Money Flows Lift Insulet
Outlier Money Flows Lift Insulet

Big Money buying shares of Insulet Corporation (PODD).

2025-05-14 07:20:10 - fxempire.com
Insulet Announces Publication of 2024 Sustainability Report
Insulet Announces Publication of 2024 Sustainability Report

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to annou

2025-05-13 06:00:00 - businesswire.com
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

2025-05-12 10:10:49 - zacks.com
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points

Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.

2025-05-10 11:47:52 - investors.com
S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks
S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of

Major U.S. equities indexes pulled back from their early gains Friday as investors wait for new developments on tariffs ahead of a weekend meeting between U.S. and Chinese officials.

2025-05-09 18:31:34 - investopedia.com
Insulet Stock Soars To A High After Robust Earnings; This Customer Management Name Pops
Insulet Stock Soars To A High After Robust Earnings; This Customer Management Na

Insulet stock soared after the company topped first quarter earnings and sales estimates. And a customer management stock hit a new high.

2025-05-09 16:02:47 - investors.com
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More

U.S. equities were mixed and little changed at midday as the markets awaited key trade talks between the U.S. and China set for this weekend. The Dow Jones Industrial Average edged lower, while the S&

2025-05-09 12:31:23 - investopedia.com
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad

Insulet Corporation  PODD reported first-quarter adjusted earnings of $1.02 per share, beating the consensus of 80 cents.

2025-05-09 11:05:57 - benzinga.com
Insulet Is the Top S&P 500 Performer Today. Here's Why.
Insulet Is the Top S&P 500 Performer Today. Here's Why.

The insulin pump maker beat earnings expectations for the first quarter and raised its forecast for 2025.

2025-05-09 10:11:00 - barrons.com
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street

2025-05-08 18:31:12 - zacks.com
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago.

2025-05-08 18:20:43 - zacks.com
Insulet beats quarterly profit estimates on insulin pump demand
Insulet beats quarterly profit estimates on insulin pump demand

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

2025-05-08 16:28:43 - reuters.com
Insulet Names New CEO, Expects to Top Revenue Projections
Insulet Names New CEO, Expects to Top Revenue Projections

Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership.

2025-04-28 10:26:04 - investopedia.com